TY - JOUR
T1 - The impact of the COVID-19 pandemic on heart failure management
T2 - Global experience of the OPTIMIZE Heart Failure Care network
AU - Cowie, Martin R.
AU - Mourilhe-Rocha, Ricardo
AU - Chang, Hung Yu
AU - Volterrani, Maurizio
AU - Ban, Ha Ngoc
AU - Campos de Albuquerque, Denilson
AU - Chung, Edward
AU - Fonseca, Cândida
AU - Lopatin, Yuri
AU - Magaña Serrano, José Antonio
AU - Mircheva, Lilyana
AU - Moncada-Paz, Gustavo Adolfo
AU - Pagava, Zurab
AU - Reyes, Eugenio B.
AU - Saldarriaga, Clara
AU - Schwartzmann, Pedro
AU - Sim Kheng Leng, David
AU - Trivi, Marcelo
AU - Yotov, Yoto Trifonov
AU - Zieroth, Shelley
N1 - Funding Information:
The OPTIMIZE Heart Failure Care program is funded by Servier , which provided support for writing assistance and the organization of working group meetings.
Funding Information:
MRC reports consultancy fees from Servier, AstraZeneca, Medtronic, Abbott, Philips, and Roche Diagnostics. RMR has received consultancy fees and speaker honoraria from Servier, AstraZeneca, Boehringer Ingelheim, Bayer and Novartis. CF has received consultancy fees, grants and speaker honoraria from AstraZeneca, Bayer, Bial, Boehringer Ingelheim, Novartis, Roche, Sanofi, Servier and Vifor Pharma. YL has received consulting and speaker fees from Boehringer Ingelheim, Servier, MSD, and Novartis. EBR has received consulting fees from E. Merck, Pfizer, Innogen, Servier, and Torrent, speaker fees from AstraZeneca, Corbridge, Servier, Pfizer, E. Merck, Novartis, Innogen, and Boehringer Ingelheim, and research grants from Novartis and Corbridge. CS has received speaker honoraria from Servier, AstraZeneca, Boehringer Ingelheim, Novartis, Medtronic, Bayer and Merck, consulting fees from Servier, Bayer, AstraZeneca, Merck and Novartis, and honoraria as a principal investigator from Bayer, Novartis, and Merck. PS has received honoraria from Servier, Novartis, Bayer, AstraZeneca and Boehringer Ingelheim. SZ has received research grant support or served on advisory boards for Abbott, Akcea, AstraZeneca, Amgen, Alnylam, Bayer, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Otsuka, Pfizer, Servier, and Vifor, she has speaker engagements Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Eli-Lilly, Novartis, Novo Nordisk, Servier, and Vifor, and she serves on a clinical trial steering committee or as a national lead for studies sponsored by AstraZeneca, Bayer, Boehringer Ingelheim, Merck and Novartis. HYC, MV, HNB, DCDA, EC, JAMS, LM, GAMP, ZP, DSKL, MT, and YTY have no competing interests to declare.
Publisher Copyright:
© 2022
PY - 2022/9/15
Y1 - 2022/9/15
N2 - During the COVID-19 pandemic, reductions in heart failure (HF) hospitalizations have been widely reported, and there is an urgent need to understand how HF care has been reorganized in countries with different infection levels, vaccination rates and healthcare services. The OPTIMIZE Heart Failure Care program has a global network of investigators in 42 countries, with first-hand experience of the impact of the pandemic on HF management in different care settings. The national coordinators were surveyed to assess: 1) the challenges of the COVID-19 pandemic for continuity of HF care, from both a hospital and patient perspective; 2) the organizational changes enacted to ensure continued HF care; and 3) lessons learned for the future of HF care. Contributions were obtained from 37 national coordinators in 29 countries. We summarize their input, highlighting the issues raised and using the example of three very different settings (Italy, Brazil, and Taiwan) to illustrate the similarities and differences across the OPTIMIZE program.
AB - During the COVID-19 pandemic, reductions in heart failure (HF) hospitalizations have been widely reported, and there is an urgent need to understand how HF care has been reorganized in countries with different infection levels, vaccination rates and healthcare services. The OPTIMIZE Heart Failure Care program has a global network of investigators in 42 countries, with first-hand experience of the impact of the pandemic on HF management in different care settings. The national coordinators were surveyed to assess: 1) the challenges of the COVID-19 pandemic for continuity of HF care, from both a hospital and patient perspective; 2) the organizational changes enacted to ensure continued HF care; and 3) lessons learned for the future of HF care. Contributions were obtained from 37 national coordinators in 29 countries. We summarize their input, highlighting the issues raised and using the example of three very different settings (Italy, Brazil, and Taiwan) to illustrate the similarities and differences across the OPTIMIZE program.
KW - Continuity of care
KW - COVID-19
KW - Heart failure
KW - Pandemic
KW - Telemedicine
UR - http://www.scopus.com/inward/record.url?scp=85133361766&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2022.06.022
DO - 10.1016/j.ijcard.2022.06.022
M3 - Article
C2 - 35750302
AN - SCOPUS:85133361766
SN - 0167-5273
VL - 363
SP - 240
EP - 246
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -